Table 2

Primary and Main Secondary Outcomes (Time to First Event) for High and Low EF

OutcomesEF ≤35%EF >35%p Value (Subgroup Interaction)
Nebivolol (n = 678)Placebo (n = 681)HR95% CINebivolol (n = 380)Placebo (n = 372)HR95% CI
Primary outcome218 (32.2)247 (36.3)0.860.72–1.04110 (29.0)125 (33.6)0.810.63–1.040.720
  (all-cause mortality or CV hospitalization)
Secondary outcomes
 All-cause mortality115 (17.0)135 (19.8)0.840.66–1.0852 (13.7)55 (14.8)0.910.62–1.330.718
 All-cause mortality or HF hospitalization170 (25.1)181 (26.6)0.940.76–1.1581 (21.3)88 (23.7)0.870.65–1.180.734
 CV mortality88 (13.0)104 (15.3)0.840.63–1.1233 (8.7)39 (10.5)0.820.52–1.300.932
 Sudden cardiac death34 (5.0)51 (7.5)0.660.43–1.029 (2.4)18 (4.8)0.490.22–1.080.510
 Non-CV mortality14 (2.1)13 (1.9)1.070.50–2.2712 (3.2)7 (1.9)1.650.65–4.190.485
 Unknown/not classified13 (1.9)18 (2.6)0.700.34–1.437 (1.8)9 (2.4)0.750.28–2.020.889
 CV hospitalization169 (24.9)180 (26.4)0.920.75–1.1485 (22.4)94 (24.3)0.830.62–1.110.593
 CV mortality or CV hospitalization204 (30.1)234 (34.4)0.860.71–1.0397 (25.5)113 (30.4)0.790.59–1.030.648
 All-cause hospitalization229 (33.8)232 (34.1)0.980.82–1.17127 (33.4)130 (35.0)0.890.70–1.140.586
 All-cause mortality or all-cause hospitalization265 (36.3)153 (41.1)0.910.77–1.08138 (36.3)153 (41.1)0.830.66–1.040.553

CI = confidence interval; CV = cardiovascular; EF = ejection fraction; HF = heart failure; HR = hazard ratio.